Literature DB >> 20945612

Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: two case reports.

J Jurado-Palomo1, R Cabañas, N Prior, I D Bobolea, A M Fiandor-Román, M C López-Serrano, S Quirce, T Bellón.   

Abstract

Drug-related rash with eosinophilia and systemic symptoms (DRESS) syndrome, or drug-induced hypersensitivity syndrome (DIHS), is a life-threatening multiorgan systemic reaction characterized by rash, fever, lymphadenopathy, hepatitis, and leukocytosis with eosinophilia. Aromatic anticonvulsant drugs and allopurinol have been reported to be the most frequent eliciting agents. Our search of the literature revealed only 2 cases induced by piperacillin and 1 case by ceftriaxone.We present 2 cases of DRESS syndrome induced by the beta-lactam drugs ceftriaxone and piperacillin-tazobactam. An allergological workup including skin prick test, intradermal tests, patch tests, and lymphocyte transformation test (LTT) was performed. LTT was shown to be a useful technique in both cases to help to identify the drugs involved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20945612

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  13 in total

Review 1.  Skin Testing for Penicillin Allergy: a Review of the Literature.

Authors:  Tracy Zembles; Michelle Mitchell; Waleed Alqurashi; Mariana Castells; Elizabeth J Phillips; David Vyles
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-18       Impact factor: 4.806

Review 2.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

Review 3.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

4.  DRESS Syndrome in the ICU: When a Patient Is Treated with Multiple Drugs.

Authors:  Florent Moriceau; Johanne Prothet; Benjamin J Blaise; Benoit Ben Said; Mathieu Page; Charles-Eric Ber; Jullien Crozon; Thomas Rimmelé
Journal:  Case Rep Crit Care       Date:  2016-01-24

5.  Immunologic evaluation of drug allergy.

Authors:  Enrique Gómez; Maria Jose Torres; Cristobalina Mayorga; Miguel Blanca
Journal:  Allergy Asthma Immunol Res       Date:  2012-05-30       Impact factor: 5.764

6.  A New Case of DRESS Syndrome Induced by Sulfasalazine and Triggered by Amoxicillin.

Authors:  Francesco Girelli; Simone Bernardi; Lucia Gardelli; Bruna Bassi; Gianluca Parente; Alessandra Dubini; Luigi Serra; Maurizio Nizzoli
Journal:  Case Rep Rheumatol       Date:  2013-07-10

7.  Acute tubular necrosis as a part of vancomycin induced drug rash with eosinophilia and systemic symptoms syndrome with coincident postinfectious glomerulonephritis.

Authors:  Kyung Min Kim; Kyoung Sung; Hea Koung Yang; Seong Heon Kim; Hye Young Kim; Gil Ho Ban; Su Eun Park; Hyoung Doo Lee; Su Young Kim
Journal:  Korean J Pediatr       Date:  2016-03-31

8.  Piperacillin/Tazobactam-Associated Hypersensitivity Syndrome with Overlapping Features of Acute Generalized Exanthematous Pustulosis and Drug-Related Rash with Eosinophilia and Systemic Symptoms Syndrome.

Authors:  Tae In Kim; Ki Heon Jeong; Min Kyung Shin; Nack In Kim
Journal:  Ann Dermatol       Date:  2016-01-28       Impact factor: 1.444

9.  Drug reaction with eosinophilia and systemic symptoms (DRESS) in children.

Authors:  Francesca Mori; Carlo Caffarelli; Silvia Caimmi; Paolo Bottau; Lucia Liotti; Fabrizio Franceschini; Fabio Cardinale; Roberto Bernardini; Giuseppe Crisafulli; Francesca Saretta; Elio Novembre
Journal:  Acta Biomed       Date:  2019-01-29

10.  Drug Fever Induced by Piperacillin/Tazobactam in a Scoliosis Patient: A Case Report.

Authors:  Zheng Li; Jianxiong Shen; Qiyi Li; Matthew Tak Vai Chan; William Ka Kei Wu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.